EC Number |
Disease |
PubMed ID |
Title of Publication |
Category |
Confidence Level |
---|
3.3.2.6 | Coinfection |
8269937 |
Coupling of recombinant 5-lipoxygenase and leukotriene A4 hydrolase activities and transcellular metabolism of leukotriene A4 in Sf9 insect cells. |
ongoing research therapeutic application unassigned |
4 1 0 |
3.3.2.6 | Neoplasms |
8615763 |
The human leukotriene A4 hydrolase gene is expressed in two alternatively spliced mRNA forms. |
causal interaction ongoing research unassigned |
1 4 0 |
3.3.2.6 | Leukemia |
8630722 |
Inhibition of leukotriene synthesis by azelastine. |
ongoing research unassigned |
4 0 |
3.3.2.6 | Lung Neoplasms |
8918363 |
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2. |
causal interaction diagnostic usage ongoing research therapeutic application |
3 3 4 3 |
3.3.2.6 | Neoplasms |
8918363 |
Lung cancer cell lines inhibit leukotriene B4 production by human polymorphonuclear leukocytes at the level of phospholipase A2. |
causal interaction diagnostic usage ongoing research therapeutic application |
3 3 4 3 |
3.3.2.6 | Dermatitis, Atopic |
8967787 |
Leukotriene A4 hydrolase in peripheral leukocytes of patients with atopic dermatitis. |
causal interaction diagnostic usage therapeutic application unassigned |
4 2 1 0 |
3.3.2.6 | Anthrax |
8973585 |
The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. |
causal interaction ongoing research therapeutic application unassigned |
2 3 1 0 |
3.3.2.6 | Psoriasis |
8982402 |
Cyclosporin A down-regulates the LTA4 hydrolase level in human keratinocyte cultures. |
therapeutic application unassigned |
4 0 |
3.3.2.6 | Melanoma |
9209681 |
Human melanoma cells generate leukotrienes B4 and C4 from leukotriene A4. |
diagnostic usage ongoing research unassigned |
3 4 0 |
3.3.2.6 | Psoriasis |
9413890 |
Significance of leukotriene-A4 hydrolase in the pathogenesis of psoriasis. |
causal interaction ongoing research therapeutic application unassigned |
4 2 4 0 |